These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25974131)

  • 1. Biosimilar insulins: guidance for data interpretation by clinicians and users.
    Heinemann L; Home PD; Hompesch M
    Diabetes Obes Metab; 2015 Oct; 17(10):911-8. PubMed ID: 25974131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.
    Tieu C; Lucas EJ; DePaola M; Rosman L; Alexander GC
    PLoS One; 2018; 13(4):e0195012. PubMed ID: 29668697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction of biosimilar insulins in Europe.
    Davies M; Dahl D; Heise T; Kiljanski J; Mathieu C
    Diabet Med; 2017 Oct; 34(10):1340-1353. PubMed ID: 28608570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar vs originator insulins: Systematic review and meta-analysis.
    Yamada T; Kamata R; Ishinohachi K; Shojima N; Ananiadou S; Nom H; Yamauchi T; Kadowaki T
    Diabetes Obes Metab; 2018 Jul; 20(7):1787-1792. PubMed ID: 29536603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilar insulins are coming: what they are, what you need to know.
    Edelman S; Polonsky WH; Parkin CG
    Curr Med Res Opin; 2014 Nov; 30(11):2217-22. PubMed ID: 25105307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of biosimilar insulins on the diabetes landscape.
    White J; Wagner A; Patel H
    J Manag Care Spec Pharm; 2022 Jan; 28(1):91-98. PubMed ID: 34726499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials.
    Heinemann L; Davies M; Home P; Forst T; Vilsbøll T; Schnell O
    J Diabetes Sci Technol; 2023 Nov; 17(6):1649-1661. PubMed ID: 35818669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars and Novel Insulins.
    Ampudia-Blasco FJ
    Am J Ther; 2020; 27(1):e52-e61. PubMed ID: 31764128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leveraging Clinical Pharmacology Data to Assess Biosimilarity and Interchangeability of Insulin Products.
    Vaidyanathan J; Wang YC; Tran D; Seo SK
    Clin Pharmacol Ther; 2023 Apr; 113(4):794-802. PubMed ID: 36052570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar Insulin and Costs: What Can We Expect?
    Heinemann L
    J Diabetes Sci Technol; 2015 Sep; 10(2):457-62. PubMed ID: 26350722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2016 Feb; 18 Suppl 1():S43-55. PubMed ID: 26836429
    [No Abstract]   [Full Text] [Related]  

  • 12. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2020 Feb; 22(S1):S32-S46. PubMed ID: 32069160
    [No Abstract]   [Full Text] [Related]  

  • 13. Administration of Biosimilar Insulin Analogs: Role of Devices.
    Heinemann L; Fritz I; Khatami H; Edelman SV
    Diabetes Technol Ther; 2017 Feb; 19(2):79-84. PubMed ID: 28118050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar insulins: a European perspective.
    DeVries JH; Gough SC; Kiljanski J; Heinemann L
    Diabetes Obes Metab; 2015 May; 17(5):445-51. PubMed ID: 25376600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review.
    Saunders H; Pham B; Loong D; Mishra S; Ashoor HM; Antony J; Darvesh N; Bains SK; Jamieson M; Plett D; Trivedi S; Yu CH; Straus SE; Tricco AC; Isaranuwatchai W
    Value Health; 2022 Jul; 25(7):1235-1252. PubMed ID: 35341688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The advent of biosimilars for the treatment of diabetes: current status and future directions.
    Polimeni G; Trifirò G; Ingrasciotta Y; Caputi AP
    Acta Diabetol; 2015 Jun; 52(3):423-31. PubMed ID: 25990669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on Biosimilar Insulins: A US Perspective.
    Zhang RM; Puri R; McGill JB
    BioDrugs; 2020 Aug; 34(4):505-512. PubMed ID: 32681425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulary Considerations for Insulins Approved Through the 505(b)(2) "Follow-on" Pathway.
    Rasmussen JT; Ipema HJ
    Ann Pharmacother; 2019 Feb; 53(2):204-210. PubMed ID: 30122087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilar insulins are coming: the top 10 things you should know.
    Blumer I; Edelman S
    Postgrad Med; 2014 May; 126(3):107-10. PubMed ID: 24918796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
    Godman B; Wladysiuk M; McTaggart S; Kurdi A; Allocati E; Jakovljevic M; Kalemeera F; Hoxha I; Nachtnebel A; Sauermann R; Hinteregger M; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Slabý J; Nejezchlebova R; Krulichová IS; Laius O; Selke G; Langner I; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuolienė K; Gulbinovič J; Bonanno PV; Rutkowski J; Ingeberg S; Melien Ø; Mardare I; Fürst J; MacBride-Stewart S; Holmes C; Pontes C; Zara C; Pedrola MT; Hoffmann M; Kourafalos V; Pisana A; Banzi R; Campbell S; Wettermark B
    Biomed Res Int; 2021; 2021():9996193. PubMed ID: 34676266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.